Results 81 to 90 of about 311,006 (351)

Surfaceome: a new era in the discovery of immune evasion mechanisms of circulating tumor cells

Molecular Oncology, EarlyView.
In the era of immunotherapies, many patients either do not respond or eventually develop resistance. We propose to pave the way for proteomic analysis of surface‐expressed proteins called surfaceome, of circulating tumor cells. This approach seeks to identify immune evasion mechanisms and discover potential therapeutic targets. Circulating tumor cells (
Doryan Masmoudi, Jérome Vialaret, Christophe Hirtz, Catherine Alix‐Panabières   +3 more
wiley   +1 more source

Tumor‐infiltrating lymphocytes for the treatment of metastatic cancer

Molecular Oncology, 2015
Over the past few years melanoma incidence has been rising steadily, resulting in an increase in melanoma related mortality. Until recently, therapeutic options for metastatic melanoma were scarce. Chemotherapy and, in some countries, IL‐2 were the only registered treatment modalities.
Geukes Foppen, M H, Donia, M, Svane, I M, Haanen, J B A G   +3 more
openaire   +4 more sources

Challenges to the development of antigen-specific breast cancer vaccines [PDF]

, 2001
Continued progress in the development of antigen-specific breast cancer vaccines depends on the identification of appropriate target antigens, the establishment of effective immunization strategies, and the ability to circumvent immune escape mechanisms.
B Thurner, BJ Van den Eynde, D Jäger, DH Kaplan, Dirk Jäger, DR Leach, E Jäger, E Jäger, FO Nestle, GP Murphy, IB Runnebaum, JJ Mule, JW Hodge, K Chikamatsu, M Marchand, MA Morse, Matthew J Scanlan, MJ Scanlan, ML Disis, ML Disis, NP Restifo, P van der Bruggen, PA Lodge, RF Wang, S Morel, S Wojtowicz-Praga, T Soussi, U Sahin, U Sahin, Y Kawakami, Y Paterson, YT Chen, YT Chen   +32 more
core   +2 more sources

Circulating tumor cells in metastatic breast cancer patients treated with immune checkpoint inhibitors – a biomarker analysis of the ALICE and ICON trials

Molecular Oncology, EarlyView.
In this explorative biomarker analysis, we assessed serial sampling of circulating tumor cells (CTCs) with CellSearch in two randomized trials testing immune checkpoint inhibitors (ICIs) in metastatic breast cancer. Our data demonstrate a prognostic potential of CTCs, most apparent 4 weeks into ICI therapy.
Nikolai Kragøe Andresen, Andreas Hagen Røssevold, Elin Borgen, Cecilie Bendigtsen Schirmer, Bjørnar Gilje, Øystein Garred, Jon Lømo, Marius Stensland, Oddmund Nordgård, Ragnhild Sørum Falk, Randi R. Mathiesen, Hege G. Russnes, Jon Amund Kyte, Bjørn Naume   +13 more
wiley   +1 more source

Tumor-infiltrating lymphocytes and response to neoadjuvant chemotherapy with or without carboplatin in human epidermal growth factor receptor 2-positive and triple-negative primary breast cancers.

Journal of Clinical Oncology, 2015
PURPOSE Modulation of immunologic interactions in cancer tissue is a promising therapeutic strategy. To investigate the immunogenicity of human epidermal growth factor receptor 2 (HER2) -positive and triple-negative (TN) breast cancers (BCs), we ...
C. Denkert, G. von Minckwitz, J. C. Brase, B. Sinn, S. Gade, R. Kronenwett, B. Pfitzner, C. Salat, S. Loi, W. Schmitt, C. Schem, K. Fisch, S. Darb-Esfahani, K. Mehta, C. Sotiriou, S. Wienert, P. Klare, F. André, F. Klauschen, J. Blohmer, K. Krappmann, Marcus Schmidt, H. Tesch, S. Kümmel, P. Sinn, C. Jackisch, M. Dietel, T. Reimer, M. Untch, S. Loibl   +29 more
semanticscholar   +1 more source

Tumor infiltrating lymphocytes in early breast cancer

The Breast, 2018
Immunoediting represents a complex and dynamic process involving cancer and immune system cells, composed by three intertwined phases: elimination, equilibrium and escape. A large number of immune cell subtypes are involved, each playing a peculiar role in interacting with cancer cells: cytotoxic CD8+ T cells play a main role in cancer killing by ...
Giancarlo Pruneri, Giancarlo Pruneri, Carsten Denkert, Andrea Vingiani   +3 more
openaire   +4 more sources

Irradiation to Improve the Response to Immunotherapeutic Agents in Glioblastomas. [PDF]

, 2019
PurposeGlioblastoma (GBM) remains an incurable disease despite extensive treatment with surgical resection, irradiation, and temozolomide. In line with many other forms of aggressive cancers, GBM is currently under consideration as a target for ...
Kaprealian, Tania, Lee, Mi-Heon, McBride, William H, Nesseler, Jean Philippe, Nickers, Philippe, Niclou, Simone P, Schaue, Dorthe   +6 more
core  

CAR-T cell. the long and winding road to solid tumors [PDF]

, 2018
Adoptive cell therapy of solid tumors with reprogrammed T cells can be considered the "next generation" of cancer hallmarks. CAR-T cells fail to be as effective as in liquid tumors for the inability to reach and survive in the microenvironment ...
A Heczey, AH Long, AM Leen, AP Cogdill, ARW Schröder, B Clémenceau, B Moldt, BD Koster, C Carpenito, C Zhang, CE Brown, CH June, CM Bollard, D Kobelt, DM Frey, DM Pardoll, DM Shayakhmetov, DW Lee, EI Buchbinder, EJ Lipson, EM Allen Van, F Bushman, F Ochi, F You, FS Hodi, G Gross, G Sconocchia, G Sconocchia, GL Beatty, H Karlsson, H Koehler, H Torikai, HC Ertl, HJ Pegram, I Caruana, J Badhiwala, J Ellis, J Wang, JE Bakema, JH Sampson, JL Tanyi, K Kono, K Kono, K Kudo, K Tamada, K Töpfer, KC Feng, L Bracci, L Zhang, LE Kandalaft, LM Rogers, LM Whilding, M Chmielewski, M Hegde, M Koneru, M Palma De, M Sadelain, M Sadelain, MA Ligtenberg, MC Milone, MCI Schalkwyk van, MD Stewart, ME Mikucki, ME Weijtens, MJ Besser, MJ Besser, MJ Butte, MJ Osborn, ML Davila, ML Davila, MM D’Aloia, MV Maus, N Ahmed, N Ahmed, O Walisko, P Kebriaei, PB Hackett, PC Schuberth, R Braster, R Monjezi, RA Morgan, RA Morgan, RJ Brentjens, RP Junghans, S Chabot, S Mohammed, S Nayak, S Sakaguchi, S Su, S Toyokuni, S Wilkie, SA Richman, SC Katz, SL Goff, SL Maude, SR Witting, SV Kulemzin, TR Medler, TR Simpson, V Arumugam, VD Fedorov, VD Sadelain, W Wang, XS Zhong, Z Eshhar, Z Grada, Z Wang   +106 more
core   +2 more sources

Circulating tumor cells: advancing personalized therapy in small cell lung cancer patients

Molecular Oncology, EarlyView.
Small cell lung cancer (SCLC) is an aggressive form of lung cancer that spreads rapidly to secondary sites such as the brain and liver. Cancer cells circulating in the blood, “circulating tumor cells” (CTCs), have demonstrated prognostic value in SCLC, and evaluating biomarkers on CTCs could guide treatment decisions such as for PARP inhibitors ...
Prajwol Shrestha, Steven Kao, Veronica K. Cheung, Wendy A. Cooper, Nico van Zandwijk, John E. J. Rasko, Dannel Yeo   +6 more
wiley   +1 more source

Hoechst Is All You Need: Lymphocyte Classification with Deep Learning [PDF]

arXiv, 2021
Multiplex immunofluorescence and immunohistochemistry benefit patients by allowing cancer pathologists to identify several proteins expressed on the surface of cells, enabling cell classification, better understanding of the tumour micro-environment, more accurate diagnoses, prognoses, and tailored immunotherapy based on the immune status of individual
arxiv